Clinical Trial

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).
Protocol Amendment History 3 changes
notable Enrollment increased: 1200 -> 1400 participants 2026-08-01
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-25
notable Primary completion pushed: 2027-01 -> 2027-08 2026-04-17
Trial Details
NCT Number NCT06993792
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight, Type 2 Diabetes
Enrollment 1,400 participants
Start Date 2025-05-15
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-31